Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease
- PMID: 3789664
- DOI: 10.1002/ana.410200408
Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease
Abstract
Although several studies have documented reduced concentrations of somatostatin-like immunoreactivity (SLI) in the cerebral cortex in Alzheimer's disease, there is controversy concerning the extent and importance of these changes. We measured SLI in brains obtained post mortem from 12 patients with pathologically confirmed Alzheimer's disease and from 13 neurologically normal controls. All major cortical and subcortical regions were examined. Widespread reductions of SLI in Alzheimer's disease cerebral cortex were found, with the most profound changes seen in temporal lobe; but there also were major reductions in both the frontal and occipital cortex. There were no significant reductions in subcortical regions. Characterization of SLI by high-pressure liquid chromatography showed no significant difference in profiles between Alzheimer's disease and control frontal cortex. These results suggest that the reduction in somatostatin immunoreactivity in Alzheimer's disease may be caused by degeneration of intrinsic somatostatin cortical neurons.
Similar articles
-
Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.Ann Neurol. 1988 Feb;23(2):105-14. doi: 10.1002/ana.410230202. Ann Neurol. 1988. PMID: 2897822
-
Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.Synapse. 1988;2(4):463-7. doi: 10.1002/syn.890020415. Synapse. 1988. PMID: 2903567
-
Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.Ann Neurol. 1988 Jun;23(6):562-9. doi: 10.1002/ana.410230606. Ann Neurol. 1988. PMID: 2900622
-
Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.Res Publ Assoc Res Nerv Ment Dis. 1986;64:259-77. Res Publ Assoc Res Nerv Ment Dis. 1986. PMID: 2425405 Review. No abstract available.
-
Neuropeptides in neurological disease.Ann Neurol. 1986 Nov;20(5):547-65. doi: 10.1002/ana.410200502. Ann Neurol. 1986. PMID: 2947536 Review.
Cited by
-
Somatostatin Ameliorates β-Amyloid-Induced Cytotoxicity via the Regulation of CRMP2 Phosphorylation and Calcium Homeostasis in SH-SY5Y Cells.Biomedicines. 2021 Jan 2;9(1):27. doi: 10.3390/biomedicines9010027. Biomedicines. 2021. PMID: 33401710 Free PMC article.
-
NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease.Acta Neuropathol. 1992;83(6):636-46. doi: 10.1007/BF00299414. Acta Neuropathol. 1992. PMID: 1378987
-
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting.Pharmacol Rev. 2024 Oct 16;76(6):1291-1325. doi: 10.1124/pharmrev.124.001117. Pharmacol Rev. 2024. PMID: 39013601 Free PMC article. Review.
-
Somatostatin and Astroglial Involvement in the Human Limbic System in Alzheimer's Disease.Int J Mol Sci. 2021 Aug 5;22(16):8434. doi: 10.3390/ijms22168434. Int J Mol Sci. 2021. PMID: 34445147 Free PMC article.
-
Somatostatin and Somatostatin-Containing Interneurons-From Plasticity to Pathology.Biomolecules. 2022 Feb 15;12(2):312. doi: 10.3390/biom12020312. Biomolecules. 2022. PMID: 35204812 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical